HC Wainwright Has Pessimistic Outlook of MNPR Q3 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities researchers at HC Wainwright decreased their Q3 2026 earnings estimates for Monopar Therapeutics in a report released on Thursday, August 13th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($0.90) per share for the quarter, down from their prior forecast of ($0.79). HC Wainwright currently has a “Buy” rating and a $125.00 target price on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($2.96) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ Q4 2026 earnings at ($1.08) EPS, FY2026 earnings at ($3.07) EPS, FY2027 earnings at ($1.46) EPS and FY2028 earnings at $0.87 EPS.

MNPR has been the topic of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. UBS Group set a $125.00 price target on Monopar Therapeutics in a research report on Thursday, July 23rd. Wall Street Zen cut Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday. Morgan Stanley reiterated an “overweight” rating and set a $130.00 price objective on shares of Monopar Therapeutics in a research report on Monday. Finally, Piper Sandler set a $105.00 price objective on Monopar Therapeutics in a research note on Tuesday, June 2nd. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $118.67.

Monopar Therapeutics Trading Up 2.2%

MNPR opened at $119.05 on Monday. Monopar Therapeutics has a twelve month low of $29.18 and a twelve month high of $124.82. The firm has a market capitalization of $798.83 million, a PE ratio of -54.86 and a beta of 1.47. The firm’s 50-day moving average price is $98.39 and its 200 day moving average price is $72.22.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.02.

Hedge Funds Weigh In On Monopar Therapeutics

Hedge funds have recently made changes to their positions in the stock. ADAR1 Capital Management LLC increased its stake in Monopar Therapeutics by 13.0% in the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after purchasing an additional 30,370 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Monopar Therapeutics by 21.2% during the first quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company’s stock worth $4,307,000 after purchasing an additional 13,761 shares in the last quarter. Siren L.L.C. lifted its position in shares of Monopar Therapeutics by 27.2% during the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after buying an additional 57,820 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Monopar Therapeutics during the 4th quarter worth approximately $654,000. Finally, Walleye Capital LLC acquired a new position in shares of Monopar Therapeutics in the 1st quarter valued at $3,458,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.